Is CCR3 a Better Target for Treatment of AMD than VEGF?
September 10, 2009
The eosinophil/mast cell receptor, CCR3, may be a better target for macular degeneration treatment than vascular endothelial growth factor. New research from the University of Kentucky, Lexington, demonstrates that CCR3 may play an integral part to development of choroidal neovascularization.
Using a mouse AMD model, blocking CCR3 inhibited the development of choroidal neovascularization. These mice lacked eosinophils and mast cells and could not mount an inflammatory response, ergo, blockage of CCR3 is not coupled to inflammation.
The researchers, including Dr. Jayakrishna Ambati, feel that CCR3 may lead to better inhibition of AMD than present anti-VEGF therapy.
Read the article.
Randall V. Wong, M.D.
Jump down to form below to submit your own comments